Viral protein interaction with cytokine and cytokine receptor
hsa04062
Chemokine signaling pathway
hsa04144
Endocytosis
hsa05170
Human immunodeficiency virus 1 infection
Metabolism
Enzyme: CYP3A4 [HSA:1576]
Interaction
Structure map
map07053
Anti-HIV agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AX Other antivirals
J05AX09 Maraviroc
D06670 Maraviroc (JAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Agents, Other
Maraviroc
D06670 Maraviroc (JAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D06670 Maraviroc (JAN/INN)
Drug groups [BR:br08330]
Antiviral
DG03107 Anti-HIV agent
D06670 Maraviroc
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D06670 Maraviroc
Drug classes [BR:br08332]
Antiviral
DG03107 Anti-HIV agent
D06670 Maraviroc
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokine receptors
Chemokine receptors
CCR5 (CD195)
D06670 Maraviroc (JAN/INN) <JP/US>
Antimicrobials [BR:br08307]
Antivirals
Entry, fusion or uncoating inhibitor
CCR5 antagonist
D06670 Maraviroc (JAN/INN) <JP/US>
Antimicrobials abbreviations [BR:br08327]
Antivirals
Entry, fusion or uncoating inhibitor
CCR5 antagonist
D06670 Maraviroc (JAN/INN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D06670
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D06670
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D06670
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06670
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D06670
Pharmacogenomic biomarkers [br08341.html]
Pathogen genome variants in infectious disease treatments
D06670
Other DBs
CAS:
376348-65-1
PubChem:
47208321
ChEBI:
63608
LigandBox:
D06670
KCF data
ATOM 37
1 C1x C 38.1872 -40.8344
2 C1x C 38.5234 -39.6913
3 C1y C 39.3302 -40.5655
4 C1y C 39.6664 -39.4224
5 N1y N 38.4561 -38.1448
6 C1x C 41.1456 -40.5655
7 C1x C 40.8766 -39.4224
8 C1y C 42.1541 -41.1034
9 C1b C 37.2458 -37.4724
10 C1b C 36.0356 -38.1448
11 N4y N 43.4322 -41.6434
12 C8y C 43.8496 -40.3900
13 N5x N 45.1958 -40.4091
14 N5x N 45.5837 -41.7142
15 C8y C 44.4584 -42.4503
16 C1c C 44.4393 -43.7966
17 C1a C 45.6040 -44.5453
18 C1a C 43.2512 -44.4616
19 C1a C 43.0462 -39.2603
20 C1c C 34.8710 -37.4724
21 N1b N 33.7064 -38.1448
22 C5a C 32.5418 -37.4724
23 C1y C 31.3772 -38.1448
24 C8y C 34.8710 -36.1280
25 C8x C 36.0516 -35.4461
26 C8x C 36.0514 -34.1013
27 C8x C 34.8869 -33.4290
28 C8x C 33.7062 -34.1109
29 C8x C 33.7064 -35.4556
30 C1x C 30.2268 -37.4806
31 C1x C 29.0623 -38.1530
32 C1z C 29.0622 -39.4977
33 C1x C 30.2123 -40.1619
34 C1x C 31.3771 -39.4896
35 O5a O 32.5418 -36.1278
36 X F 27.8867 -40.1764
37 X F 27.8796 -38.8148
BOND 41
1 1 2 1
2 1 3 1
3 2 4 1
4 3 5 1
5 3 6 1
6 4 7 1
7 6 8 1
8 4 5 1
9 7 8 1
10 9 10 1
11 5 9 1
12 8 11 1
13 11 12 1
14 12 13 2
15 13 14 1
16 14 15 2
17 11 15 1
18 15 16 1
19 16 17 1
20 16 18 1
21 12 19 1
22 10 20 1
23 20 21 1
24 21 22 1
25 22 23 1
26 20 24 1 #Up
27 24 25 1
28 25 26 2
29 26 27 1
30 27 28 2
31 28 29 1
32 24 29 2
33 23 30 1
34 30 31 1
35 31 32 1
36 32 33 1
37 33 34 1
38 23 34 1
39 22 35 2
40 32 36 1
41 32 37 1